SLP-1A6

SLP-1A6 is a small molecule therapeutic candidate developed by MetCure Therapeutics that targets the interaction between Embryonic Ectoderm Development (EED) and Enhancer of Zeste Homolog 2 (EZH2). By disrupting this interaction or inducing the degradation of the complex components, SLP-1A6 acts as an epigenetic modulator to inhibit the activity of the Polycomb Repressive Complex 2 (PRC2). PRC2 is responsible for the trimethylation of histone H3 at lysine 27 (H3K27me3), a modification associated with transcriptional repression that is frequently hijacked in various malignancies. SLP-1A6 is currently in early-stage development for the treatment of cancer, with published work highlighting its use in LC-MS/MS method validation for pharmacokinetic studies.